S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   399.69 (+2.17%)
AAPL   160.24 (+2.19%)
MSFT   336.63 (+2.11%)
FB   338.03 (+1.47%)
GOOGL   2,910.61 (+2.35%)
AMZN   3,561.57 (+1.63%)
TSLA   1,136.99 (+5.09%)
NVDA   333.76 (+5.95%)
BABA   131.61 (-1.30%)
NIO   40.46 (+1.18%)
CGC   11.06 (-5.39%)
AMD   161.91 (+4.59%)
GE   98.40 (+0.57%)
MU   86.14 (+3.26%)
T   23.89 (-1.36%)
F   19.67 (-0.41%)
DIS   147.81 (-0.20%)
ACB   6.44 (-5.15%)
AMC   36.84 (-2.10%)
PFE   52.40 (-2.96%)
BA   198.50 (-0.36%)
NASDAQ:XLO

Xilio Therapeutics Stock Forecast, Price & News

$15.20
-4.71 (-23.66%)
(As of 11/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.68
$20.59
50-Day Range
N/A
52-Week Range
$14.68
$27.95
Volume
165,855 shs
Average Volume
132,554 shs
Market Capitalization
$405.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive XLO News and Ratings via Email

Sign-up to receive the latest news and ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Xilio Therapeutics logo

About Xilio Therapeutics

Xilio Therapeutics Inc. is a biotechnology company which focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company's product candidate includes XTX101, XTX202, XTX301 and XTX401 which are in clinical stage. Xilio Therapeutics Inc. is based in WALTHAM, Mass.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Research and Development in Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XLO
Web
N/A
Phone
N/A
Fax
N/A
Employees
2,021
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$405.32 million
Optionable
Not Optionable

Company Calendar

Today
11/29/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

561st out of 1,392 stocks

Research And Development In Biotechnology Industry

1st out of 4 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Xilio Therapeutics (NASDAQ:XLO) Frequently Asked Questions

Is Xilio Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xilio Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Xilio Therapeutics stock.
View analyst ratings for Xilio Therapeutics
or view top-rated stocks.

What price target have analysts set for XLO?

4 analysts have issued twelve-month target prices for Xilio Therapeutics' stock. Their forecasts range from $31.00 to $32.00. On average, they anticipate Xilio Therapeutics' stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price.
View analysts' price targets for Xilio Therapeutics
or view top-rated stocks among Wall Street analysts.

When did Xilio Therapeutics IPO?

(XLO) raised $125 million in an initial public offering (IPO) on Friday, October 22nd 2021. The company issued 7,353,000 shares at $16.00-$18.00 per share.

What is Xilio Therapeutics' stock symbol?

Xilio Therapeutics trades on the NASDAQ under the ticker symbol "XLO."

When does Xilio Therapeutics' quiet period expire?

Xilio Therapeutics' quiet period expires on Wednesday, December 1st. Xilio Therapeutics had issued 7,353,000 shares in its IPO on October 22nd. The total size of the offering was $117,648,000 based on an initial share price of $16.00. During Xilio Therapeutics' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Xilio Therapeutics?

Shares of XLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xilio Therapeutics' stock price today?

One share of XLO stock can currently be purchased for approximately $15.20.

How much money does Xilio Therapeutics make?

Xilio Therapeutics has a market capitalization of $405.32 million.

How many employees does Xilio Therapeutics have?

Xilio Therapeutics employs 2,021 workers across the globe.


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.